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1. INTRODUCTION {#jcla23003-sec-0005}
===============

Lung cancer is a common malignant tumor. According to the Chronic Disease Monitoring Report of the Zhejiang Province (2017), the incidence rate of lung cancer was 80.51/100 000, and 84.72/100 000 in the city, and 78.16/100 000 in the countryside, as well as 99.37/100 000 among males, and 61.33/100 000 among females.[1](#jcla23003-bib-0001){ref-type="ref"} Lung cancer is ranked as the first cause of cancer‐related death in the Zhejiang Province. A total of 26 788 deaths were reported in 2017, and the reported mortality rate was 55.65/100 000. The reported mortality rates in the city and the countryside were 52.04/100 000 and 58.03/100 000, respectively. The mortality of lung cancer increases with age; the mortality rate among the elderly (\>65 years) reached 299.2/100 000.[1](#jcla23003-bib-0001){ref-type="ref"} These alarming incidence rate and mortality of lung cancer statistics may due to the lack of effective early diagnostic methods of lung cancer. Currently, surgical resection is the main effective therapy for lung cancer. However, most lung cancer patients have lost the chances for surgery for quite of them are not diagnosed until at metastatic or even advanced stages.[2](#jcla23003-bib-0002){ref-type="ref"} Therefore, it is crucial to explore potential molecular targets for early detection or intervention/treatment of lung cancer, thereby reducing the mortality of lung cancer.

MicroRNA (miRNA) is a widespread class of non‐coding small RNA, and its mature state is a kind of single‐chain small molecule RNA with a length of about 19‐23 nucleotides. Mature miRNA mainly inhibits the translation of target mRNA by the complementary base pairing of 3‐untranslated region (UTR), 5‐UTR and the coding region of target mRNA, which regulates the expression of target genes at the post‐transcriptional level. The study of bioinformatics has shown that single miRNA molecules can bind to hundreds of target mRNAs with different functions and play regulatory roles in almost all mammalian pathological and physiological activities, such as individual development, tissue differentiation, cell apoptosis, and energy metabolism and are closely associated with the occurrence and development of diseases. In recent years, some studies reported that serum/plasma miRNA expression profile could effectively distinguish between cancer patients and healthy individuals and might be related to the development of lung cancer[3](#jcla23003-bib-0003){ref-type="ref"}, [4](#jcla23003-bib-0004){ref-type="ref"}, [5](#jcla23003-bib-0005){ref-type="ref"} or might have potential clinical value in the early diagnosis, prognostic, and therapeutic of lung cancer.[6](#jcla23003-bib-0006){ref-type="ref"}, [7](#jcla23003-bib-0007){ref-type="ref"}, [8](#jcla23003-bib-0008){ref-type="ref"}, [9](#jcla23003-bib-0009){ref-type="ref"}, [10](#jcla23003-bib-0010){ref-type="ref"} However, the functions of miRNA remain unclear. Therefore, we used a miRNA chip screening system for lung cancer, and then, real‐time fluorescent quantitative PCR (RT‐PCR) verification method to investigate the difference of plasma miRNA expression profile between lung cancer patients and healthy controls to predict target genes and to analyze the signal pathways, and to explore the relationship between miRNA and the genesis and the development of lung cancer.

2. SUBJECTS AND METHODS {#jcla23003-sec-0006}
=======================

2.1. Subjects {#jcla23003-sec-0007}
-------------

A total of 145 lung adenocarcinoma patients were recruited from various county‐level hospitals in the Zhejiang Province, diagnosed with first primary lung cancer (confirmed by histopathology), Most of the stages for the lung cancer cases are either T1 or T2. Not all the stages for the lung cancer cases are available, although we made great efforts to collect. The reason might be that some patients' histology and stages were diagnosed in hospitals of other provinces like Shanghai, but treated at their local hospitals without diagnostic materials in medical records.

Patients did not receive any surgery, chemotherapy, or radiotherapy before fasting venous blood collection. Healthy individuals (without any kind of cancer, frequency matched with cases by age \[±5 years\] and gender) for chronic disease screening were recruited from the community during the same period and fasting venous blood were collected. Participants were asked about their smoking status. Those who responded as abstained smoking means they smoked but abstained for more than 1 year. Occasionally smoking was defined as those who occasionally smokes but does not meet the frequently smoking standard. Frequently smoking was defined as smoking every day for more than 1 year. People who did not smoke were defined as never smokers.

For microarray chip screening, we first randomly selected three patients, who were frequency matched with three randomly selected healthy individuals from the community during the same period (matched with age \[±5 years\] and gender). The six blood samples of the three patients and three healthy individuals were used first for microarray chip screening of differentially expressed miRNAs, then for validation by RT‐PCR. The information on the three cases and three controls is as follows: (a) all three cases were diagnosed as having adenocarcinoma of the lung; (b) in the three patients and three healthy individuals, the male/female rations are both 2/1, and the ages are 61 ± 12 and 62 ± 10 years for cases and controls, respectively; (c) one lung cancer patients were smoker matched with one smoking healthy control, the other 4 participants are all never smokers. The differences in the age and gender between the two groups were not significant.

In the second stage, all the blood samples of the 145 lung adenocarcinoma patients' and frequency‐matched 55 healthy individuals' were used for a larger sample validation of differentially expressed miRNAs by RT‐PCR. The age, gender distribution, family history of lung cancer and smoking status of participants are shown in Table [1](#jcla23003-tbl-0001){ref-type="table"}, and no significant differences were observed between the two groups.

###### 

General information of the study subjects for verification by using fluorescent quantitative PCR in large sample

  Subjects                        Lung cancer patients (145)   Healthy controls (55)   ORc (95% CI)
  ------------------------------- ---------------------------- ----------------------- ----------------------
  Gender (M/F)                    100/45                       30/25                   1.852 (0.980‐3.501)
  Age (year)                      62 ± 11                      65 ± 13                 1.022 (0.993‐1.051)
  Family history of lung cancer                                                        
  No = 0                          135                          54                      1.00
  Yes = 1                         10                           1                       0.250 (0.031‐2.001)
  Smoking                                                                              
  Never                           63                           44                      1.00
  Abstained                       63                           0                       1.187 (0.497‐2.836)
  Occasionally                    2                            1                       0.000 (0.000)
  Frequently                      17                           10                      0.850 (0.068‐10.610)

Abbreviation: ORc: Crude OR.
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2.2. Experimental procedures {#jcla23003-sec-0008}
----------------------------

### 2.2.1. RNA extraction and quality control {#jcla23003-sec-0009}

Plasma RNA was extracted by the TRIzol method and purified with RNasey Mini Kit (Qiagen). NanoDrop ND‐1000 (Thermo) was used to measure the concentration of purified RNA and detect the quality of RNA. The integrity of the RNA was detected by denaturing agarose gel electrophoresis.

### 2.2.2. RNA labeling and microarray chip hybridization {#jcla23003-sec-0010}

RNA labeling and microarray chip hybridization were performed according to the method and instructions provided by Exiqon (Exiqon A/S Skelstedet 162950).

### 2.2.3. Microarray chip scanning {#jcla23003-sec-0011}

Microarray chip scanning was performed by using Axon GenePix 4000B microarray chip scanner (Molecular Devices) according to the manufacturer\'s instructions.

### 2.2.4. Real‐time fluorescent quantitative PCR verification (RT‐PCR) {#jcla23003-sec-0012}

The cDNA synthesis of both target miRNA and reference miRNA (hsa‐miR‐93‐5p) was performed after quality inspection and used for RT‐PCR, respectively. The volume of reaction was 10 µL. The detection of target miRNA and reference hsa‐miR‐93‐5p was performed according to the following procedure: 95°C for 10 minutes; then, 40 cycles of each (95°C for 10 seconds, 60°C for 60 seconds \[fluorescence collection\]). The melting curve of RT‐PCR products was established according to the following procedure: 95°C for 10 seconds, 60°C for 60 seconds, and 95°C for 15 seconds after amplification. Then slowly heated from 60 to 99°C (Ramp Rate was automatically set to 0.05°C/s by the instrument).

The expression of target miRNA was corrected with reference miRNA. The volume of 2 µL was used for each sample for RT‐PCR. The hsa‐miR‐93‐5p (the expression level is constant among different samples) was used as a reference. The sequences of related primers are shown in Table [2](#jcla23003-tbl-0002){ref-type="table"}.

###### 

List of primers for real‐time quantitative PCR and the results of fluorescent quantitative PCR verification

  Genes                      Primers                         Annealing temperature (°C)   Product length (bp)   Fold change (lung cancer case group vs healthy control group)   *P* value
  -------------------------- ------------------------------- ---------------------------- --------------------- --------------------------------------------------------------- -----------------------------------------------
  hsa‐miR‐93‐5p              GSP:5′GGCAAAGTGCTGTTCGTG3′      60                           65                                                                                     
  R:5′CAGTGCGTGTCGTGGAGT3′                                                                                                                                                      
  Upregulated miRNAs                                                                                                                                                            
  hsa‐miR‐3655               GSP:5′AGGCTTGTCGCTGCGGT3′       60                           61                    0.77                                                            .320
  R:5′GTGCGTGTCGTGGAGTCG3′                                                                                                                                                      
  hsa‐miR‐450b‐5p            GSP:5′GGGGTTTTGCAATATGTTCC3′    60                           64                    1.53                                                            .003[\*](#jcla23003-note-0004){ref-type="fn"}
  R:5′GTGCGTGTCGTGGAGTCG3′                                                                                                                                                      
  hsa‐miR‐29a‐5p             GSP:5′GGGACTGATTTCTTTTGGT3′     60                           65                    4.08                                                            .003[\*](#jcla23003-note-0004){ref-type="fn"}
  R:5′CAGTGCGTGTCGTGGA3′                                                                                                                                                        
  hsa‐miR‐542‐3p             GSP: 5′GGGGTGTGACAGATTGATAA3′   60                           66                    1.79                                                            .014[\*](#jcla23003-note-0004){ref-type="fn"}
  R:5′CAGTGCGTGTCGTGGAGT3′                                                                                                                                                      
  hsa‐miR‐138‐5p             GSP:5′GGGGCTGGTGTTGTGAATC3′     60                           63                    1.56                                                            .045[\*](#jcla23003-note-0004){ref-type="fn"}
  R:5′GTGCGTGTCGTGGAGTCG3′                                                                                                                                                      
  hsa‐miR‐502‐5p             GSP:5′GGGGAATCCTTGCTATCTGG3′    60                           64                    0.99                                                            .946
  R:5′GTGCGTGTCGTGGAGTCG3′                                                                                                                                                      
  hsa‐miR‐4491               GSP:5′GGGGAATGTGGACTGGTGTG3′    60                           64                    2.21                                                            .034[\*](#jcla23003-note-0004){ref-type="fn"}
  R:5′GTGCGTGTCGTGGAGTCG3′                                                                                                                                                      
  hsa‐miR‐192‐5p             GSP:5′GGGGCTGACCTATGAATTG3′     60                           65                    1.78                                                            .097
  R:5′CAGTGCGTGTCGTGGAGT3′                                                                                                                                                      
  Downregulated miRNA                                                                                                                                                           
  hsa‐miR‐34c‐5p             GSP:5′GGGAGGCAGTGTAGTTAGC3′     60                           66                    0.69                                                            .148
  R:5′CAGTGCGTGTCGTGGAGT3′                                                                                                                                                      
  hsa‐miR‐135a‐5p            GSP:5′GGGGTATGGCTTTTTATTCCT3′   60                           65                    0.23                                                            .002[\*](#jcla23003-note-0004){ref-type="fn"}
  R:5′GTGCGTGTCGTGGAGTCG3′                                                                                                                                                      
  hsa‐miR‐1246               GSP:5′GGGGAATGGATTTTTGG3′       60                           63                    0.23                                                            .016[\*](#jcla23003-note-0004){ref-type="fn"}
  R:5′CAGTGCGTGTCGTGGAG3′                                                                                                                                                       
  hsa‐miR‐125a‐5p            GSP:5′GCTCCCTGAGACCCTTTA3′      60                           66                    0.15                                                            .058
  R:5′CAGTGCGTGTCGTGGAGT3′                                                                                                                                                      

GSP is the specific primer corresponding to miRNA; R is the primer that matched with RT primer. The fold change of lung cancer case group vs healthy control group \>1 was considered as upregulation, and \<1 was considered as downregulation.

Indicates *P* ≤ .05 (significant).
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2.3. Target gene prediction {#jcla23003-sec-0013}
---------------------------

Target gene prediction was performed by using the information of three database tools including miRbase, miRanda, and TargetScan. TopGO analysis was performed for the target genes.

2.4. The methods for data analysis {#jcla23003-sec-0014}
----------------------------------

All data were analyzed using SPSS 13.0 software. The continuous variables were presented as the means ± SD. The univariate logistic regression analysis was performed to assess associations with gender, age, family history of lung cancer and smoking (multi‐categorical variables transformed into dummy variables) between the cases and controls, and group variable (cases = 1, controls = 0) was used as the dependent variable (sls = 0.1, sle = 0.05).

2.5. Analysis of miRNA expression profiling {#jcla23003-sec-0015}
-------------------------------------------

The microarray chip scanning image was read by using GenePix Pro 6.0 (Molecular Devices), and the signal value of the probes was extracted. The Exiqon miRCURY LNA™ microRNA microarray chip contains 3100 probes, covering all human, mouse, and rat microRNA annotated by miRbase 18.0 and also the viral microRNA related to these species.

Each probe has four repeats on the microarray chip, retaining the probes with value ≥30.0 in all samples and calculating the median value. All of the probes with the signal value ≥30 were screened for median value standardization among the microarray chips to obtain the standardized data, and the differentially expressed probes were screened. Standardization can minimize the system error among microarray chips so that different microarray chips are comparable. Fold change and *P*‐value were used in this experiment for miRNAs selection with Fold Change ≥2.0, *P‐*value ≤ .05.

2.6. Results analysis of the RT‐PCR for verification {#jcla23003-sec-0016}
----------------------------------------------------

The results of the RT‐PCR for verification were analyzed by using 2^−ΔΔ^ *^C^* ^T^ method. Lung cancer cases group 2^−ΔΔ^ *^C^* ^T^/Healthy control group 2^−ΔΔ^ *^C^* ^T^ \> 1 was considered as upregulation. Lung cancer cases group 2^−ΔΔ^ *^C^* ^T^/Healthy control group 2^−ΔΔ^ *^C^* ^T^ \< 1 was considered as downregulation. *P* ≤ .05 was considered as significant.

2.7. Target gene prediction and signaling pathway analysis {#jcla23003-sec-0017}
----------------------------------------------------------

### 2.7.1. Target gene prediction {#jcla23003-sec-0018}

Target gene prediction was performed by using the information of three databases including miRbase, miRanda, and TargetScan. The overlapping part of the predictive results derived from the three databases was defined as the final prediction results. The association strength of the Overlap number \>3 and Overlap‐coefficient \>0.5 was used as the default screening index.

### 2.7.2. Gene ontology (GO) analysis {#jcla23003-sec-0019}

The GO project provides a controlled vocabulary to describe gene and gene product attributes in any organism.[11](#jcla23003-bib-0011){ref-type="ref"} The ontology covers three domains: Biological Process (BP), Cellular Component (CC), and Molecular Function (MF). Fisher\'s exact test is used to find if there is more overlap between the DE list and the GO annotation list than would be expected by chance. The *P‐*value denotes the significance of GO terms enrichment in the DE genes. The lower the *P‐*value, the more significant the GO Term (to our above described 12 miRNAs, *P‐* value ≤ .01 was selected).

### 2.7.3. Signaling pathway analysis {#jcla23003-sec-0020}

Pathway analysis is a functional analysis of mapping genes to Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. The *P‐*value was calculated by the Fisher Exact Test that denotes the significance of the pathway correlated to the conditions. Lower the *P‐*value, more significant is the pathway. *P* \< .05 was used in our study as the threshold to obtain the high‐frequency annotation, signaling transduction, and disease‐related pathway of the gene set. miRNA_GO_Network map was drawn by using gene sets correlation analysis from the miRNA and BP enrichment analysis in GO.

3. RESULTS {#jcla23003-sec-0021}
==========

3.1. Preliminary screening of miRNA Array chip {#jcla23003-sec-0022}
----------------------------------------------

Three hundred and thirty‐eight differentially expressed miRNAs were identified through initial microarray chip analysis. Among them, 204 were significantly upregulated, and 134 were significantly downregulated (Fold Change ≥2.0, *P‐*value ≤ .05). According to the fold changes, the top ten upregulated miRNAs were hsa‐miR‐124‐3p, hsa‐miR‐379‐5p, hsa‐miR‐3655, hsa‐miR‐450b‐5p, hsa‐miR‐29a‐5p, hsa‐miR‐200a‐3p, hsa‐miR‐542‐3p, hsa‐miR‐138‐5p, hsa‐miR‐219a‐2‐3p, and hsa‐miR‐4701‐3p, and the top ten downregulated miRNAs were hsa‐miR‐34c‐5p, hsa‐miR‐135a‐5p, hsa‐miR‐132‐3p, hsa‐miR‐3178, hsa‐miR‐4449, hsa‐miR‐4999‐3p, hsa‐miR‐1246, hsa‐miR‐4424, hsa‐miR‐1252‐5p, and hsa‐miR‐24‐2‐5p.

3.2. RT‐PCR verification {#jcla23003-sec-0023}
------------------------

According to the microarray chip screening results and literature reports, 12 miRNAs (Table [2](#jcla23003-tbl-0002){ref-type="table"}) were then selected for the verification by using RT‐PCR.

The results of the RT‐PCR verification showed that among the chosen 12 miRNAs, 5 of 8 significantly upregulated miRNAs showed significant difference between the lung cancer group and the healthy control group (*P* \< .05, all of them were upregulated); 2 of 4 significantly downregulated miRNAs showed significant difference between the two groups (*P* \< .05, both of them kept downregulated) (Table [2](#jcla23003-tbl-0002){ref-type="table"}). The amplification and melting curves (not shown in paper) showed that the RT‐PCR reaction had good amplification efficiency and specificity.

3.3. Target gene prediction {#jcla23003-sec-0024}
---------------------------

The overlapping part of the predictive results derived from three databases including miRbase, miRanda, and TargetScan were selected, which showed a total of eight miRNAs in the overlapping part of predictive results derived from the three databases. The eight miRNAs and the number of their predictive target genes were as follows: hsa‐miR‐125a‐5p with 102 target genes, hsa‐miR‐135a‐5p with 91 target genes, hsa‐miR‐138‐5p with 45 target genes, hsa‐miR‐192‐5p with 22 target genes, hsa‐miR‐34c‐5p with 64 target genes, hsa‐miR‐450b‐5p with 67 target genes, hsa‐miR‐502‐5p with 27 target genes, and hsa‐miR‐542‐3p with 35 target genes, for a total of 453 target genes (Figure not shown). GO and signaling pathway enrichment analysis of the predictive 453 target genes were performed.

3.4. GO analysis and GO cluster enrichment analysis of predictive target genes {#jcla23003-sec-0025}
------------------------------------------------------------------------------

The GO analysis showed a large amount of functional overlapping among the 453 predicted target genes. In addition, they were enriched in BP including cellular macromolecule metabolic process, cell cycle regulation, cellular protein metabolic process, positive regulation of the BP, cellular protein modification process, and intracellular signal transduction; in the CC including intracellular, intercellular, cytoplasm, organelle part, ion channel complex, and stress fiber; and in the MF including protein binding, nucleotide binding, and protein kinase activity, (*P* \< .01) (Tables [3](#jcla23003-tbl-0003){ref-type="table"}).

###### 

The Gene Ontology (GO) biological process (BP), cellular component (CC), and molecular function (MF) analysis of target genes

  GO.ID        Term                                        Category   The number of target genes   *P* value
  ------------ ------------------------------------------- ---------- ---------------------------- -------------
  GO:0044260   Cellular macromolecule metabolic process    BP         237                          1.53207E‐06
  GO:0007049   Cell cycle                                  BP         70                           1.61085E‐06
  GO:0048522   Positive regulation of cellular process     BP         148                          1.63651E‐06
  GO:0044267   Cellular protein metabolic process          BP         153                          2.91601E‐06
  GO:0048518   Positive regulation of biological process   BP         165                          4.43874E‐06
  GO:0006464   Cellular protein modification process       BP         123                          5.37341E‐06
  GO:0036211   Protein modification process                BP         123                          5.37341E‐06
  GO:0035556   Intracellular signal transduction           BP         94                           1.08515E‐05
  GO:0022402   Cell cycle process                          BP         54                           1.64587E‐05
  GO:0006793   Phosphorus metabolic process                BP         103                          1.85407E‐05
  GO:0005622   Intracellular                               CC         346                          1.24301E‐06
  GO:0044424   Intracellular part                          CC         338                          3.26228E‐06
  GO:0005623   Cell                                        CC         379                          3.83014E‐05
  GO:0044464   Cell part                                   CC         377                          0.000112113
  GO:0005737   Cytoplasm                                   CC         269                          0.000131442
  GO:0005829   Cytosol                                     CC         99                           0.00020604
  GO:0044422   Organelle part                              CC         212                          0.000559938
  GO:0043229   Intracellular organelle                     CC         290                          0.000657913
  GO:0034702   Ion channel complex                         CC         16                           0.000695189
  GO:0001725   Stress fiber                                CC         6                            0.000864451
  GO:0032553   Ribonucleotide binding                      MF         68                           4.09233E‐05
  GO:0005515   Protein binding                             MF         272                          4.68665E‐05
  GO:0032555   Purine ribonucleotide binding               MF         67                           5.7016E‐05
  GO:0017076   Purine nucleotide binding                   MF         67                           6.72523E‐05
  GO:0000166   Nucleotide binding                          MF         78                           0.000151141
  GO:1901265   Nucleoside phosphate binding                MF         78                           0.000153272
  GO:0004672   Protein kinase activity                     MF         28                           0.000184924
  GO:0032550   Purine ribonucleoside binding               MF         64                           0.000193572
  GO:0001883   Purine nucleoside binding                   MF         64                           0.000202749
  GO:0032549   Ribonucleoside binding                      MF         64                           0.000202749

John Wiley & Sons, Ltd

3.5. Enrichment analysis of signaling transduction pathway {#jcla23003-sec-0026}
----------------------------------------------------------

Pathway enrichment analysis based on KEGG was performed on the predictive target genes set through DAVID database and the signaling pathways with *P* \< .05 were selected (Figure [1](#jcla23003-fig-0001){ref-type="fig"}). The results showed a large amount of overlapping among the signaling transduction pathways of predictive target genes set. The KEGG pathway analysis involved several disease‐related pathways including transcriptional misregulation in cancer, proteoglycans in cancer, mRNA surveillance pathway, RNA degradation, cAMP signaling pathway, dopaminergic synapses, and vascular smooth muscle contraction (*P* \< .05) (Table [4](#jcla23003-tbl-0004){ref-type="table"}).

![miRNA_GO_Network analysis](JCLA-33-na-g001){#jcla23003-fig-0001}

###### 

The Enrichment analysis of signaling transduction pathway

  PathwayID   Definition                                                       The number of target genes   *P* value
  ----------- ---------------------------------------------------------------- ---------------------------- ------------
  hsa03015    mRNA surveillance pathway---Homo sapiens (human)                 8                            .00173546
  hsa04728    Dopaminergic synapse---Homo sapiens (human)                      9                            .004934847
  hsa04270    Vascular smooth muscle contraction---Homo sapiens (human)        8                            .009863016
  hsa04261    Adrenergic signaling in cardiomyocytes---Homo sapiens (human)    9                            .0111802
  hsa05205    Proteoglycans in cancer---Homo sapiens (human)                   11                           .01188643
  hsa05202    Transcriptional misregulation in cancer---Homo sapiens (human)   10                           .01285791
  hsa04360    Axon guidance---Homo sapiens (human)                             8                            .01298216
  hsa03013    RNA transport---Homo sapiens (human)                             9                            .02525796
  hsa04024    cAMP signaling pathway---Homo sapiens (human)                    10                           .02583363
  hsa04713    Circadian entrainment---Homo sapiens (human)                     6                            .0322689
  hsa00052    Galactose metabolism---Homo sapiens (human)                      3                            .0367944
  hsa03018    RNA degradation---Homo sapiens (human)                           5                            .04100519
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3.6. Validation by RT‐PCR {#jcla23003-sec-0027}
-------------------------

According to the screening results by microarray, the RT‐PCR verification results of microarray chip samples and the literature reports, four miRNAs including hsa‐miR‐29a‐5p, hsa‐miR‐135a‐5p, hsa‐miR‐542‐3p, and hsa‐miR‐4491 were selected for differentially expressed miRNAs verification by RT‐PCR in a large sample of 145 first‐episode lung cancer patients and 55 healthy controls. The experimental approaches, reference genes, and data analysis methods were the same as the RT‐PCR validation experiments in the microarray chip samples. The results showed that the difference of expression level of hsa‐miR‐29a‐5p, hsa‐miR‐135a‐5p, hsa‐miR‐542‐3p, and hsa‐miR‐4491 between the lung cancer group and the control group showed significance (*P* \< .05), which were in accordance with the upregulation/downregulation trend of the screening results by microarray and the RT‐PCR verification results of microarray chip samples (Figure [2](#jcla23003-fig-0002){ref-type="fig"}).

![Results of the larger sample validation by real‐time fluorescence quantitative PCR (RT‐PCR). *Note*: tumor = lung cancer patients; normal = healthy controls. The fold change of the lung cancer group vs the healthy control group \>1 was considered as upregulation, \<1 was considered as downregulation; \**P* ≤ .05 (significant), \*\*\**P* ≤ .001 (significant), \*\*\*\**P* ≤ .0001 (significant)](JCLA-33-na-g002){#jcla23003-fig-0002}

Multiple comparisons might lead to false positives. We conducted multistage of validations among large samples of cases and controls in order to reduce potential multiple comparison false‐positive issues. We have attempted using a 2‐stage approach. In the discovery stage, we identified 338 differentially expressed microRNAs, but only 12 microRNAs were identified in the further PCR confirmation. We were not able to adjust for multiple comparisons because of relatively small sample size. In the confirmation/validation stage, among 12 microRNAs, we eventually identified four microRNAs with *P*‐value \<.05. If we use Bonferroni correction (0.05/12 = 0.00417), three microRNAs are statistically significant hsa‐miR‐542‐3p, hsa‐miR‐4491, and hsa‐miR‐135a‐5p.

4. DISCUSSION {#jcla23003-sec-0028}
=============

Studies have shown that miRNAs are abnormally expressed in a variety of tumors such as lung cancer,[5](#jcla23003-bib-0005){ref-type="ref"}, [6](#jcla23003-bib-0006){ref-type="ref"}, [7](#jcla23003-bib-0007){ref-type="ref"}, [10](#jcla23003-bib-0010){ref-type="ref"}, [12](#jcla23003-bib-0012){ref-type="ref"} breast cancer,[13](#jcla23003-bib-0013){ref-type="ref"} and liver cancer.[14](#jcla23003-bib-0014){ref-type="ref"} More than 50% of the miRNA genes have been located in tumor‐related genomic regions or fragile sites.[15](#jcla23003-bib-0015){ref-type="ref"} The miRNAs can act not only as tumor suppressor genes to downregulate the activity oncogenes but also to downregulate the activity of tumor suppressor genes. miRNAs can also affect the development and progression of tumors by intervening cell cycle, apoptosis, angiogenesis, and metastasis.[9](#jcla23003-bib-0009){ref-type="ref"}, [16](#jcla23003-bib-0016){ref-type="ref"}, [17](#jcla23003-bib-0017){ref-type="ref"} So far, only a very few of the miRNAs and their regulating target genes had been identified, and the functions of most miRNAs were still unclear. Further studies are needed on the functions of miRNAs to search for new miRNAs to accurately predict their target genes and correctly understand the interactions of miRNA and its target genes.

To date, the total number of miRNAs that was included in the latest version of miRbase22.1 database[11](#jcla23003-bib-0011){ref-type="ref"} had exceeded 38 000 precursor sequences, and a total of mature miR and miR\* products of 48 885 covering a total of 168 species in mirbase18.0 that are mentioned in this article. With the development of a high‐throughput detection technology of miRNA, an increasing number of new miRNA have been discovered. The ambiguous and incorrectly commented sequences in miRbase database were constantly cleared, and the reliability of the database was continuously improved. MiRNA microarray is the most commonly used method for high‐throughput detection of large amount of miRNA specific expression in tumor samples.[18](#jcla23003-bib-0018){ref-type="ref"} Compared with traditional RNA analysis methods, it has the following advantages: (a) high‐throughput joint detection; (b) the detection efficiency and sensitivity are high; and (c) sample demanded is small, and only 1 µg of total RNA can complete all the tests, which has great significance for tumor samples that are extremely difficult to obtain.

As a research method of expression spectroscopy, it is difficult to avoid false‐positive results for the miRNA chip. Therefore, it is necessary to verify the chip screened miRNA. Although RT‐PCR is a low‐throughput detection method, it has high detection sensitivity and can faithfully reflect the abundance of miRNA in samples. Further, RT‐PCR verification of large samples can more truly reflect the actual expression of miRNA. Accordingly, the quality controls in the RT‐PCR analysis are very important, as in our study, we (a) measured the concentration of purified RNA and detected the quality of RNA before RT‐PCR analysis, (b) used hsa‐miR‐93‐5p as a reference and the expression of target miRNA was corrected with reference miRNA, (c) The negative template control was performed in the RT‐PCR analysis, (d) melt curve and application curve are used to determine the specificity of the products, (e) the results of the RT‐PCR for verification were analyzed by using 2^−ΔΔ^ *^C^* ^T^ method and the differentially expressed probes were screened.

General human tissue could express miRNA, studies also showed that miRNA might not be degraded by endogenous RNase in serum and plasma and could still exist in a very stable form in harsh conditions (such as high temperature, low or high pH environment, and multiple freeze‐thaw). Moreover, the expression profiles of miRNA in the serum and plasma of normal people and patients with different diseases would be specifically changing with the physiological status, disease type, and disease courses. Based on this, this study used microRNA chip with 3100 probes and screened out a total of 338 miRNAs which are differentially expressed in lung cancer patients and healthy controls. Among them, 204 miRNAs were significantly increased, and 134 miRNAs were significantly downregulated. In the 12 miRNAs which were verified by RT‐PCR, seven miRNAs were confirmed. RT‐PCR validation results of large samples suggested hsa‐miR‐29a‐5p, hsa‐miR‐135a‐5p, hsa‐miR‐542‐3p, and hsa‐miR‐4491 could be used as candidate genes for early screening of lung cancer, and three of these microRNAs, except hsa‐miR‐29a‐5p, were significant after Bonferroni correction for adjustment of multiple comparisons. These results illustrated that RT‐PCR verification results were highly consistent with miRNA chip results, suggesting that miRNA chip detection is an efficient, rapid, and high‐throughput method for the analysis of miRNA differential expression between lung cancer patients and healthy controls, while RT‐PCR is suitable for the study of individual gene expression changes. The two methods could complement and confirm each other.

Previous studies showed that miRNA family is an important part of the gene expression regulatory network and might be involved in the regulation of multiple signaling pathways.[19](#jcla23003-bib-0019){ref-type="ref"}, [20](#jcla23003-bib-0020){ref-type="ref"}, [21](#jcla23003-bib-0021){ref-type="ref"} The determination of miRNA target gene was the key to study the biological function of miRNA, and the functional analysis of target gene was helpful to understand the functional mechanism of miRNA. Bioinformatics prediction showed that miRNAs could regulate more than 30% of protein‐coding genes.[22](#jcla23003-bib-0022){ref-type="ref"} An individual miRNA could act on a number of target genes to regulate biological processes, while multiple miRNAs could also regulate some of the target genes. Through the analysis, 12 differentially expressed miRNAs that we selected participated in the regulation of 37 281 predicted target genes and functioned in a variety of physiological processes. Further analysis showed that the 12 miRNAs had 453 overlapped predicted target genes; through the analysis of target genes, we found that the collection functions of target genes were also highly coincident suggesting that the regulation of target genes by miRNA had a synergistic effect. When a few miRNAs were commonly upregulated in tissues, the inhibition of a target gene would be strengthened, and vice versa.

The KEGG pathway analysis showed a large amount of overlapping among the signal transduction pathway of target gene sets, which are involved in cancer transcriptional dysregulation pathway, proteoglycan, and cancer pathway, suggesting that it might be closely related to the cancers such as lung cancer. Studies suggested that hsa‐miR‐29a family could inhibit the protein expression of B7‐H3 and perform inhibition effects on a variety of B7‐H3 protein‐mediated solid tumors, including lung cancer, and hsa‐miR‐29a mutation could promote the growth of tumor cells[23](#jcla23003-bib-0023){ref-type="ref"}; hsa‐miR‐29a in the peripheral circulation in lung cancer patients could bind and activate toll‐like receptors (TLR) in immune cells around tumors. Activation of TLRs could trigger NF‐κB pathway, leading to an increase in the expressions of IL‐6 and TNF‐α in immune cells and increasing the potential for tumor growth and metastasis,[24](#jcla23003-bib-0024){ref-type="ref"} which was consistent with the results of this study, suggesting that hsa‐miR‐29a was involved in the pathological process of lung cancer. Although the relationship between hsa‐miR‐4491 and lung cancer has not been reported, our study suggested that it might play an important role in the pathogenesis of lung cancer. According to another report, miR‐542‐3p was located in Xq26.3 and was downregulated in non--small‐cell lung cancer and breast cancer. It could directly target survival protein or angiopoietin‐2, respectively, resulting in growth arrest and angiogenesis inhibition. miR‐542‐3p acts as a tumor suppressor gene,[25](#jcla23003-bib-0025){ref-type="ref"}, [26](#jcla23003-bib-0026){ref-type="ref"} which is inconsistent with the high expression of miR‐542‐3p in lung cancer cases in this study. Zhang Hongyan et al[27](#jcla23003-bib-0027){ref-type="ref"} investigated miR‐135a expression and clinical pathology of lung cancer and found that miR‐135a was closely related to the clinical stage and pathological grade of lung cancer. The serum miR‐135a level was downregulated in non--small‐cell lung carcinoma (NSCLC) patients and was associated with poor prognosis. It can be used as a biomarker for NSCLC prognosis.[28](#jcla23003-bib-0028){ref-type="ref"} Zhou\'s findings indicated that miR‐135a promotes cell apoptosis and inhibits cell proliferation, migration, invasion, and tumor angiogenesis by targeting IGF‐1 gene through the IGF‐1/PI3K/Akt signaling pathway in NSCLC,[29](#jcla23003-bib-0029){ref-type="ref"} and MiR‐135a inhibits migration and invasion and regulates EMT‐related marker genes by targeting KLF8 in lung cancer cells,[30](#jcla23003-bib-0030){ref-type="ref"} which is consistent with our study, while Zhang\'s study showed that MiR‐135a overexpression promoted viability, migration, and invasion, but inhibited apoptosis of NCI‐H1650 and NCI‐H1975 cells.[31](#jcla23003-bib-0031){ref-type="ref"} Our subsequent cell biology experiments supported our results that the overexpression of mir‐135a‐5p could inhibit the invasion of adenocarcinoma cells, and the overexpression of mir‐542‐3p could promote the proliferation of adenocarcinoma cells (data not shown). Taken together, the results suggest that there are divergences in the expression and function of various miRNAs in lung cancer, which might be due to that the upregulation or downregulation of miRNA mainly dependent on the types of tissue and the target proteins of miRNA. We cannot simply define a specific miRNA as a tumor suppressor gene or an oncogene. In one cell system, it may be an oncogene, while in another it may be a tumor suppressor gene. And these areas need further studies.

In summary, we screened the miRNA expression profile which was closely related to lung cancer by using miRNA microarray and bioinformatics approaches. In addition, target prediction showed that lung cancer‐related miRNA targets were very extensive, involving the genes including oncogenes, tumor suppressor genes, signal transduction genes, and cell cycle regulation related genes, which would provide a new experimental basis and ideas for the further research on the effect of miRNA on the occurrence and development of lung cancer in future.
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